E
Evommune, Inc. (EVMN)
NYQ – Real vaqt narxi. Valyuta: USD
25.18
+1.05 (4.35%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
25.17
-0.01 (-0.04%)
Bozordan keyin: Jun 26, 2026, 6:40 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
25.18
+1.05 (4.35%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
25.17
-0.01 (-0.04%)
Bozordan keyin: Jun 26, 2026, 6:40 PM EDT
Evommune, Inc. Qo'shma Shtatlarda klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya surunkali yallig'lanish kasalliklarining asosiy sabablarini maqsad qilgan terapiyalarni ishlab chiqadi, dastlabki klinik rivojlanish dasturlari surunkali spontan ürtiker, atopik dermatit va yarali kolitga qaratilgan. Mahsulotlariga CSU va ADni davolash uchun EVO756; va AD va UCni davolash uchun EVO301 kiradi. Kompaniya 2020 yilda tashkil etilgan va Palo Alto, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Mr. J. Mark Jackson M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-02 | 8-K | evmn-20260602.htm |
| 2026-05-07 | 8-K | evmn-20260507.htm |
| 2026-05-07 | 10-Q | evmn-20260331.htm |
| 2026-04-22 | CORRESP | filename1.htm |
| 2026-04-21 | DEF 14A | evmn-20260421.htm |
| 2026-04-21 | ARS | evmn-2026-proxy-ars.pdf |
| 2026-04-17 | S-1 | d127341ds1.htm |
| 2026-04-13 | 8-K | evmn-20260413.htm |
| 2026-03-05 | S-8 | evmn-20260305.htm |
| 2026-03-05 | 8-K | evmn-20260305.htm |
| Senior Vice President of Clinical Development |
| Mr. Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Mr. Luis C. Pena | Founder, President, CEO & Director |
| Ms. Janice Drew M.P.H. | Chief of Development Operations |